activities in this
vaccine trial network
as part of a €150 million
EU investment in research
to fight coronavirus variants
European Corona Vaccine Trial Accelerator
This is a great place to tell your story and give people more insight into who you are, what you do, and why it’s all about you.
mainly affect low income population
have the potential to cause global outbreaks
Neglected and emerging infectious diseases disproportionately affect the lives of people and children living in low- and middle-income countries, causing sickness, disability and death to millions, and also represent a significant and growing threat worldwide.
Vaccines are among the most successful and cost-effective public health tools for preventing diseases and death. Each year, more than three million lives are saved and millions more are protected from disease and disability, thanks to vaccination.
Vaccines, the way forward
Malaria is caused by Plasmodium
parasites and spread to people through mosquitoes. 90% of all cases occur in the WHO Africa Region.
Leishmaniasis is caused by a protozoan parasite and transmitted to humans by sandflies. Over 1 billion people are at risk from leishmaniasis.
Nipah virus can be transmitted from animals (pigs, bats), contaminated food or directly between people. The case fatality rate ranges from 40% to 100%.
Zika is an emerging mosquito-borne virus. Zika virus infection during pregnancy can cause infants to be born with congenital Zika syndrome.
EVI is committed to supporting vaccine development beyond individual vaccine candidates. EVI engages in initiatives aimed at creating harmonisation between stakeholders, promote networking and support access to vaccine infrastructures as well as capacity strengthening activities at the European and global level.
EVI is committed to establishing a European vaccine R&D infrastructure to accelerate the development of prophylactic and therapeutic vaccines for human and animal health.
EVI is supporting the development and validation of non-animal approaches for testing quality of human and veterinary vaccines.
Diarrhoeal diseases are the 2nd leading cause of death in children under five. Shigella and Enterotoxigenic E. coli are major causes of diarrhoea worldwide.
EVI seeks to create sustainable health networking, knowledge hubs and facilitate
cooperation of mutual benefit in health research and innovation.
EVI is working across Europe to harmonise key vaccine assays, through standardised lab procedures, preparations, and reagents, and by promoting their uptake and use.
Since its inception in 1998, EVI has succeeded in establishing and maintaining an ‘enabling environment’ that accelerates vaccine development and has developed synergies and collaborations with multiple partners, including other Product Development Partnerships (PDPs), academia, research institutions, pharma and biotechnology companies, policy makers regulatory agencies and donors.
In 2020, EVI supported: